What Initial Reopenings Teach Us About Virus Safety Plans

2020 ◽  
Author(s):  
Isaac Mamaysky
Keyword(s):  
Virus Safety

scholarly journals Approaching virus safety in xenotransplantation: a search for unrecognized herpesviruses in pigs

2003 ◽  
Vol 10 (4) ◽  
pp. 349-356 ◽  
Author(s):  
Barbara Chmielewicz ◽  
Michael Goltz ◽  
Karl-Heinz Lahrmann ◽  
Bernhard Ehlers
Keyword(s):  
Virus Safety

scholarly journals Yttrium-90 glass-based microsphere radioembolization in the treatment of hepatocellular carcinoma secondary to the hepatitis B virus: safety, efficacy, and survival

2015 ◽  
Vol 26 (2) ◽  
pp. S29
Author(s):  
D.M. Biederman ◽  
E.S. Pierobon ◽  
J.J. Titano ◽  
L. Karen ◽  
M. Schwartz ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
B Virus ◽  
Virus Safety ◽  
Yttrium 90

Monoclonal Antibody Production: Minimising Virus Safety Issues

Antibodies ◽  
2004 ◽  
pp. 199-225
Author(s):  
John Bray ◽  
Malcolm K. Brattle
Keyword(s):  
Monoclonal Antibody ◽  
Antibody Production ◽  
Monoclonal Antibody Production ◽  
Safety Issues ◽  
Virus Safety

scholarly journals Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma

Blood ◽  
1992 ◽  
Vol 79 (3) ◽  
pp. 826-831 ◽  
Author(s):  
B Horowitz ◽  
R Bonomo ◽  
AM Prince ◽  
SN Chin ◽  
B Brotman ◽  
...  
Keyword(s):  
Sindbis Virus ◽  
Animal Studies ◽  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Complete Inactivation ◽  
Virus Safety ◽  
Fresh Frozen ◽  
History Of ◽  
Triton X ◽  
Frozen Plasma

Abstract Fresh frozen plasma (FFP) is prepared in blood banks world-wide as a by- product of red blood cell concentrate preparation. Appropriate clinical use is for coagulation factor disorders where appropriate concentrates are unavailable and when multiple coagulation factor deficits occur such as in surgery. Viral safety depends on donor selection and screening; thus, there continues to be a small but defined risk of viral transmission comparable with that exhibited by whole blood. We have prepared a virus sterilized FFP (S/D-FFP) by treatment of FFP with 1% tri(n-butyl)phosphate (TNBP) and 1% Triton X-100 at 30 degrees C for 4 hours. Added reagents are removed by extraction with soybean oil and chromatography on insolubilized C18 resin. Treatment results in the rapid and complete inactivation of greater than or equal to 10(7.5) infectious doses (ID50) of vesicular stomatitis virus (VSV) and greater than or equal to 10(6.9) ID50 of sindbis virus (used as marker viruses), greater than or equal to 10(6.2) ID50 of human immunodeficiency virus (HIV), greater than or equal to 10(6) chimp infectious doses (CID50) of hepatitis B virus (HBV), and greater than or equal to 10(5) CID50 of hepatitis C virus (HCV). Immunization of rabbits with S/D-FFP and subsequent adsorption of elicited antibodies with untreated FFP confirmed the absence of neoimmungen formation. Coagulation factor content was comparable with that found in FFP. Based on these laboratory and animal studies, together with the extensive history of the successful use of S/D-treated coagulation factor concentrates, we conclude that replacement of FFP with S/D-FFP, prepared in a manufacturing facility, will result in improved virus safety and product uniformity with no loss of efficacy.

Clinical evaluation of virus safety and inhibitor incidence

1995 ◽  
Vol 6 (Sup 2) ◽  
pp. S86-S92 ◽  
Author(s):  
M. Buyse ◽  
J-L. Poplavsky
Keyword(s):  
Clinical Evaluation ◽  
Virus Safety

Investigations of prion and virus safety of a new liquid IVIG product

Biologicals ◽  
2008 ◽  
Vol 36 (4) ◽  
pp. 239-247 ◽  
Author(s):  
M. Stucki ◽  
N. Boschetti ◽  
W. Schäfer ◽  
T. Hostettler ◽  
F. Käsermann ◽  
...  
Keyword(s):  
Virus Safety

Virus safety of a porcine-derived medical device: Evaluation of a viral inactivation method

2002 ◽  
Vol 79 (2) ◽  
pp. 211-216 ◽  
Author(s):  
Jason Hodde ◽  
Michael Hiles
Keyword(s):  
Medical Device ◽  
Viral Inactivation ◽  
Virus Safety

Virus Safety of Prothrombin Complex Concentrates and Factor IX Concentrates

1999 ◽  
Vol 95 (4) ◽  
pp. S19-S23 ◽  
Author(s):  
Rainer Seitz ◽  
Johannes Dodt
Keyword(s):  
Factor Ix ◽  
Prothrombin Complex Concentrates ◽  
Virus Safety

Virus safety of plasma derivatives

1990 ◽  
Vol 11 ◽  
pp. S1-S2
Author(s):  
P.M. Mannucci
Keyword(s):  
Virus Safety

scholarly journals Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.

1991 ◽  
Vol 35 (7) ◽  
pp. 1469-1473 ◽  
Author(s):  
J R Groothuis ◽  
M J Levin ◽  
W Rodriguez ◽  
C B Hall ◽  
C E Long ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
High Risk ◽  
Gamma Globulin ◽  
Study Group ◽  
Virus Safety ◽  
Intravenous Gamma Globulin ◽  
Syncytial Virus ◽  
High Risk Children
Sign in / Sign up

Export Citation Format

Share Document